1122 GMT - The U.S. Food and Drug Administration's request for a label warning about Guillain-Barre syndrome risk on GSK's respiratory syncytial virus shot Arexvy could negatively impact vaccine sales, Bryan Garnier Research analysts say in a note. While a causal link between vaccination and GBS-- a rapid-onset muscle weakness caused by the immune system-- hasn't been proven, seven GBS cases per million Arexvy doses were observed, according to the FDA. "We believe the observed GBS incidence very close to natural GBS incidence in the non-vaccinated population," the analysts say. Arexvy sales already declined double-digit in 2H of 2024, following the narrowed recommendation to a smaller age range and more at-risk patients, the analysts say. Shares fall 0.04% at 1359.50 pence.(helena.smolak@wsj.com)
(END) Dow Jones Newswires
January 09, 2025 06:24 ET (11:24 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.